Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

被引：8
|
作者：
Duliege, Anne-Marie [1 ]
Arnold, Donald M. [2 ]
Boccia, Ralph [3 ]
Boxer, Michael [4 ]
Cooper, Nichola [5 ]
Hill, Quentin A. [6 ]
Liles, Darla K. [7 ]
Sholzberg, Michelle [8 ]
Zayed, Hany [1 ]
Tong, Sandra [1 ]
Bussel, James B. [9 ]
机构：
[1] Rigel Pharmaceut Inc, San Francisco, CA USA
[2] McMaster Univ, Dept Med, Michael G DeGroote Sch Med, Hamilton, ON, Canada
[3] Ctr Canc & Blood Disorders, Bethesda, MD USA
[4] Arizona Oncol, Tucson, AZ USA
[5] Imperial Coll NHS Trust, London, England
[6] St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England
[7] East Carolina Univ, Vidant Med Ctr, Div Hematol Oncol, Greenville, NC 27858 USA
[8] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[9] New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Pediat, Div Pediat Hematol Oncol, New York, NY USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110482
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
736
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis
    Mayo, Marlyn J.
    Vierling, John M.
    Bowlus, Christopher L.
    Levy, Cynthia
    Hirschfield, Gideon M.
    Neff, Guy W.
    Galambos, Michael R.
    Gordon, Stuart C.
    Borg, Brian B.
    Harrison, Stephen A.
    Thuluvath, Paul J.
    Goel, Aparna
    Shiffman, Mitchell L.
    Swain, Mark G.
    Jones, David E. J.
    Trivedi, Palak
    Kremer, Andreas E.
    Aspinall, Richard J.
    Sheridan, David A.
    Doerffel, Yvonne
    Yang, Ke
    Choi, Yun-Jung
    McWherter, Charles A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 186 - 200
  • [2] Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial
    Brunner, Hermine I.
    Ruperto, Nicolino
    Zuber, Zbigniew
    Cuttica, Ruben
    Keltsev, Vladimir
    Xavier, Ricardo M.
    Burgos-Vargas, Ruben
    Penades, Inmaculada Calvo
    Silverman, Earl D.
    Espada, Graciela
    Zavaler, Manuel Ferrandiz
    Kimura, Yukiko
    Duarte, Carolina
    Job-Deslandre, Chantal
    Joos, Rik
    Douglass, Wendy
    Wimalasundera, Sunethra
    Bharucha, Kamal N.
    Wells, Chris
    Lovell, Daniel J.
    Martini, Alberto
    de Benedetti, Fabrizio
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (03) : 530 - 541
  • [3] Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study
    Kuter, David J.
    Bussel, James B.
    Newland, Adrian
    Wasser, Jeffrey S.
    Lyons, Roger M.
    George, James N.
    Macik, Gail
    Nie, Kun
    Jun, Susie
    BLOOD, 2010, 116 (21) : 36 - 37
  • [4] EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A TWO-YEAR OPEN-LABEL EXTENSION STUDY
    Goldman, Robert S.
    Tocco, Michael
    Pikalov, Andrei A.
    Deng, Ling
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2018, 57 (10): : S160 - S160
  • [5] Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study
    Bussel, James B.
    Kuter, David J.
    Newland, Adrian
    de Wolf, Joost T. M.
    Wasser, Jeffrey
    Chang, Paul
    Nie, Kun
    Berger, Dietmar
    BLOOD, 2009, 114 (22) : 285 - 285
  • [6] Safety and Efficacy Of Long-Term Open-Label Romiplostim Dosing In Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
    Tarantino, Michael D.
    Bussel, James B.
    Geddis, Amy
    Guerrera, Michael F.
    Ikeda, Alan K.
    Nie, Kun
    Eisen, Melissa
    BLOOD, 2013, 122 (21)
  • [7] Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Puig, Luis
    Lebwohl, Mark
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Gomez, Natalie Nunez
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 486 - 495
  • [8] Efficacy and Safety of Avatrombopag in Japanese Adults with Chronic Immune Thrombocytopenia: Open-Label, Phase 3 Study
    Yamaguchi, Hiroki
    Iino, Masaki
    Imamura, Yutaka
    Kowata, Shugo
    Yamamoto, Ryusuke
    Yamanouchi, Jun
    Fujii, Masato
    Zhang, Jessica
    Tomiyama, Yoshiaki
    Jamieson, Brian
    BLOOD, 2024, 144 : 5426 - 5427
  • [9] Safety and Efficacy of Long-Term Open-Label Dosing of Romiplostim in Thrombocytopenic Pediatric Patients (Pts) with Immune Thrombocytopenia (ITP)
    Bussel, James B.
    Tarantino, Michael D.
    Geddis, Amy
    Guerrera, Michael F.
    Ikeda, Alan K.
    Nie, Kun
    Franklin, Janet
    Eisen, Melissa
    BLOOD, 2014, 124 (21)
  • [10] Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)
    Tarantino, Michael D.
    Bussel, James B.
    Blanchette, Victor S.
    Despotovic, Jenny M.
    Bennett, Carolyn
    Raj, Ashok
    Williams, Bronwyn
    Beam, Donald
    Morales, Jaime
    Rose, Melissa J.
    Nie, Kun
    Eisen, Melissa
    BLOOD, 2015, 126 (23)
12345